STAT+: The numbers that tell a scary story about the state of biotech
The black mood in biotech investing has, somehow, worsened.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
This newsletter is gloomy, but soon Boston’s evening skies will be brighter, longer. Welcome back, daylight saving time! Goodbye, seasonal affective disorder.
Biotech is in an even darker place
How is that possible? I don’t know, it just is. The black mood in biotech investing that I described just a few weeks ago has, somehow, worsened.
